ArticleEnvironmental science and pollution research international2021
Environmental risk assessments of multiclass pharmaceutical active compounds: selection of high priority concern pharmaceuticals using entropy-utility functions.
Article in Environmental science and pollution research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advantages and drawbacks of life cycle assessment application to the pharmaceuticals: a short critical literature review.Environmental science and pollution research international · 2026Review
- Economic Entropy and the Cobb-Douglas Function: A Scientometric Analysis.Entropy (Basel, Switzerland) · 2026Article
- Critical insights into the potential risks of antipsychotic drugs to fish, including through effects on behaviour.Biological reviews of the Cambridge Philosophical Society · 2025Review
- Occurrence and removal of psychiatric pharmaceuticals in the Tehran South Municipal Wastewater Treatment Plant.Environmental science and pollution research international · 2023Article
- An Overview of Analytical Methods to Determine Pharmaceutical Active Compounds in Aquatic Organisms.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research aimed to identify high-risk pharmaceutically active compounds (PhACs) by analyzing occurrence (O), persistence (P), bioaccumulation (B), and toxicity (T) of 62 drugs which are widely used in Iran. A comprehensive approach was taken in risk assessment of the selected PhACs and in their prioritization using multiple-criteria decision analysis (MCDA) such as utility functions and principal component analysis (PCA). In practice, assigning weight to each criterion (i.e., O, P, B, and T) for risk assessment of PhACs is a challenge. In this research, the impact of giving both equal and unequal weight to each criterion by using a quantitative entropy method was studied. For risk assessment, two exposure approaches (consumption rate and occurrence of PhACs) and three MCDA approaches (PCA and utility functions with and without equal weights for each criterion) were compared. The utility function using equal weights for all O, P, B, and T criteria showed that thioridazine, pimozide, chlorpromazine, sertraline, clomipramine, and aripiprazole were at the highest level of risk, with concern score of 0.75, 0.75, 0.67, 0.58, 0.58, and 0.58, respectively. Unequal weight approach included additional compounds such as fluoxetine, citalopram, and methadone as a priority. All three MCDA approaches showed that sedatives and antidepressants were prevalent PhACs in the risk-based priority lists. However, the exposure-based approaches showed antibiotics and analgesics as the pharmaceutical of the highest priority. Overall, selection of the high priority concern pharmaceuticals depends on the prioritization approach employed. However, the utility function using unequal weights is a more conservative and effective approach for prioritization.
Indexed as
Identifiers
34146330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.